Introducing PHIL (precipitating hydrophobic injectable liquid) - a new embolic agent for the body interventional radiologist

A number of embolic agents are currently available each with their own properties. Precipitating hydrophobic injectable liquid (PHIL) is a new dimethyl sulfoxide (DMSO) compatible embolic agent with a number of specific properties which make it of interest to interventional radiologists. We review t...

Full description

Saved in:
Bibliographic Details
Published in:Diagnostic and interventional radiology (Ankara, Turkey) Turkey), 2020-03, Vol.26 (2), p.140-142
Main Authors: Prashar, Akash, Butt, Saqib, Shaida, Nadeem
Format: Article
Language:English
Subjects:
Computed tomography
Dimethyl sulfoxide
Dimethyl Sulfoxide - administration & dosage
Dimethyl Sulfoxide - therapeutic use
Discoloration
Embolization
Embolization, Therapeutic - methods
Free Radical Scavengers - administration & dosage
Free Radical Scavengers - therapeutic use
Humans
Hydrophobic and Hydrophilic Interactions
Hydrophobicity
Injections
Interventional Radiology
Product introduction
Radiology, Interventional - methods
Tranexamic acid
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A number of embolic agents are currently available each with their own properties. Precipitating hydrophobic injectable liquid (PHIL) is a new dimethyl sulfoxide (DMSO) compatible embolic agent with a number of specific properties which make it of interest to interventional radiologists. We review the use of PHIL in a non-neurointerventional setting, describing its use in a range of procedures such as trauma embolization, pseudoaneurysm embolization, and tumor embolization. PHIL's properties include a lack of skin discoloration, the possibility of rapid injection and a lack of glare artifact on follow-up computed tomography imaging. These properties make it an important new tool in the armamentarium of the body interventional radiologist.
ISSN:1305-3612
1305-3825
1305-3612
DOI:10.5152/dir.2019.19063